Pierfrancesco Tassone

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Arlene Chan, Suzette Delaloge, Frankie A. Holmes et al. · The Lancet Oncology · 2016 · 565 citations

Medicine, Oncology, Breast Oncology +13

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

Mariateresa Fulciniti, Pierfrancesco Tassone, Teru Hideshima et al. · Blood · 2009 · 398 citations · Full text

Medicine, Immunology, Oncology +10

BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells

Pierfrancesco Tassone, Pierosandro Tagliaferri, Alessia Perricelli et al. · British Journal of Cancer · 2003 · 359 citations · Full text

Medicine, Molecular Genetics, Oncology +12

Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

Laurence Catley, Ellen Weisberg, Tanyel Kiziltepe et al. · Blood · 2006 · 340 citations · Full text

Medicine, Oncology, Pharmacology +17